BP | HER2 type | 5NP | Total | |
---|---|---|---|---|
Cases, n (%) | 61 (40.4) | 60 (39.7) | 30 (19.5) | 151 (100) |
Median age at diagnosis, years (IQR) | 72 (65–80) | 67 (58.5–74.5) | 73.5 (66–83) | 71 (64–78) |
Median follow-up time, years (IQR) | 4.9 (2.4–11.2) | 3.2 (1.3–9.4) | 3.9 (2.5–10.3) | 3.8 (1.6–10.5) |
Median time to breast cancer death, years (IQR) | 2.5 (1.3–3.7) | 1.7 (1.0–3.1) | 3.0 (2.0–4.5) | 2.4 (1.2–3.7) |
Death from breast cancer, n (%) | ||||
Yes | 34 (55.7) | 23 (38.3) | 14 (46.7) | 71 (47.0) |
No | 27 (44.3) | 37 (61.7) | 16 (53.3) | 80 (53.0) |
Grade, n (%) | ||||
1 | 2 (3.3) | 0 (0.0) | 0 (0.0) | 2 (1.3) |
2 | 7 (11.5) | 10 (16.7) | 18 (60.0) | 35 (23.2) |
3 | 52 (85.3) | 50 (83.3) | 12 (40.0) | 114 (75.5) |
Tumour diameter (mm), n (%) | ||||
≤20 | 25 (41.0) | 19 (31.7) | 9 (30.0) | 53 (35.1) |
>20, ≤50 | 12 (19.7) | 3 (5.0) | 4 (13.3) | 19 (12.6) |
>50 | 2 (3.3) | 1 (1.7) | 2 (6.7) | 5 (3.3) |
Uncertain, but ≥20 | 10 (16.4) | 22 (36.7) | 10 (33.3) | 42 (27.8) |
Unknown | 12 (19.7) | 15 (25.0) | 5 (16.7) | 32 (21.2) |
Lymph node status, n (%) | ||||
Negative | 19 (31.2) | 15 (25.0) | 5 (16.7) | 39 (25.8) |
Negative, less than five nodes examined | 5 (8.2) | 4 (6.7) | 3 (10.0) | 12 (8.0) |
Positive | 26 (42.6) | 33 (55.0) | 14 (46.7) | 73 (48.3) |
Unknown (not examined) | 11 (18.0) | 8 (13.3) | 8 (26.7) | 27 (17.9) |
Stage, n (%) | ||||
I | 25 (41.0) | 23 (38.3) | 13 (43.3) | 61 (40.4) |
II | 30 (49.2) | 27 (45.0) | 13 (43.3) | 70 (46.4) |
III+IV | 6 (9.8) | 10 (16.7) | 4 (13.3) | 20 (13.3) |
Ki67 status, n (%) | ||||
<15% | 10 (16.4) | 12 (20.0) | 17 (56.7) | 39 (25.8) |
≥15% | 50 (82.0) | 48 (80.0) | 13 (43.3) | 111 (73.5) |
Median MVD, microvessels/mm2 (IQR) | 72.7 (49.6–99.8) | 83.6 (60.6–125.7) | 122.0 (70.4–182.8) | 83.6 (55.5–120.0) |
Median pMVD, microvessels/mm2 (IQR) | 2.3 (1.2–4.6) | 2.9 (1.2–6.3) | 2.5 (1.2–6.9) | 2.3 (1.2–5.2) |
Median VPI, percentage points (IQR) | 3.6 (1.4–7.1) | 4.1 (1.6–6.3) | 2.3 (0.8–6.5) | 3.6 (1.2–6.7) |
5NP, five negative phenotype; BP, basal phenotype; HER2, human epidermal growth factor receptor 2; MVD, microvessel density; pMVD, proliferating microvessel density; VPI, vascular proliferation index.